Post by PharmaShots

Novartis receives EC approval for Itvisma to treat spinal muscular atrophy, with P-III data showing significant motor function improvement and becoming the first gene replacement therapy in the EU for patients aged 2+ Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #novartis #spinalmuscularatrophy #itvisma #piii #steer #piiib #strength #strong #genereplacementtherapy #genetherapy #ec #approval #regulatory #neurology #raredisease https://lnkd.in/d7b2A-Pn